Drug Regulation

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (November 09-November 15)

After a busy week featuring several interesting and important posts on some pressing questions in Indian IP law and policy, we are back to kick off the week with another edition of the SpicyIP Weekly Review. This Weekly Review brings together discussions on a range of issues, from the proposed introduction of data exclusivity and its implications for India’s pharmaceutical landscape to the limits of territorial jurisdiction in IP disputes and the evolving contours of personality rights. Anything we are

SpicyIP Weekly Review (November 09-November 15) Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (November 2 — November 8)

After a long weekend, we’re back with our weekly roundup of important and interesting IP updates, featuring posts on the NPPA TMR order, ABS, and a comment on evidence-based IP policymaking. We apologise for the delay in bringing you this week’s edition, which is going out a little later than usual. This, and much more, in this edition of the SpicyIP Weekly Review! This Weekly Review is authored by Adyasha Syam. Adyasha is a third-year law student at National Law

SpicyIP Weekly Review (November 2 — November 8) Read More »

[Part III] The Trial of Data Exclusivity

In the third part of the post on data exclusivity (see here for Part I and Part II), Arnav explores whether there are alternative ways to incentivise domestic pharmaceutical innovation and clinical trials without introducing a data exclusivity regime. In this post, he examines possible policy interventions and alternative models, including a compensatory liability framework, while also highlighting the need for meaningful public consultation before any such policy decisions are made. Arnav is a 5th-year law student from Rajiv Gandhi

[Part III] The Trial of Data Exclusivity Read More »

[Part II] The Trial of Data Exclusivity

Continuing the discussion on the proposed introduction of data exclusivity in India, in Part II of his three-part post, Arnav examines its potential implications for domestic innovation, access to medicines, foreign investment, and the conduct of clinical trials. He also questions whether data exclusivity would address the underlying challenges facing India’s clinical trial ecosystem, and whether the promised benefits would justify the costs to public health and the domestic pharmaceutical industry. Arnav is a 5th-year law student from Rajiv Gandhi

[Part II] The Trial of Data Exclusivity Read More »

Taping the Pipe: NPPA’s Trade Margin Cap on Anti-Cancer Drugs

Suppose there is a leak in your water supply pipe, and instead of replacing the pipe, you keep wrapping tape around the crack. The drip stops, for now but the pipe is still cracked, and you have only deferred the day it bursts. Policy-making on affordable medicines in India more or less follows the same approach, and the recent National Pharmaceutical Pricing Authority’s (NPPA) Trade Margin Rationalisation (TMR) order for anti-cancer drugs is its latest example. In this post, I

Taping the Pipe: NPPA’s Trade Margin Cap on Anti-Cancer Drugs Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (October 26-November 1)

Announcing the 2026 Shamnad Basheer Essay Competition, a post on the ongoing Cadila-Hetero biosimilar dispute ahead of the Supreme Court hearing, and posts on the Indian Designs Office’s draft GUI Guidelines and the Trade Marks Registry’s proposed framework for the use of AI in proceedings. This and much more in this week’s SpicyIP Weekly Review. Anything we are missing out on? Drop a comment and let us know. Highlights of the Week Announcing the 2026 Shamnad Basheer Essay Competition on

SpicyIP Weekly Review (October 26-November 1) Read More »

Letting the Plaintiff Examine Regulator’s Approvals: Unpacking the DHC’s Cadila-Hetero Discovery Order Ahead of the SC Hearing

[Thanks to Swaraj Barooah sharing an in-progress draft from a project he is working on examining cancer litigation in India. The questions in there led me to write this post.] Can a court say a company has no right to confidentiality in its regulatory data, and then hand that data to a rival’s expert in a sealed cover? The Delhi High Court decided it can. On 3 November 2026, the Supreme Court is scheduled to take up two Special Leave

Letting the Plaintiff Examine Regulator’s Approvals: Unpacking the DHC’s Cadila-Hetero Discovery Order Ahead of the SC Hearing Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (October 12-October 18)

[This Weekly Review is prepared by Kaustub Boidi. Kaustub is a final-year law student at SVKM’s NMIMS, Hyderabad.] Here’s this week’s roundup of IP developments, from posts on the Kerala High Court’s Ribociclib decision, the Delhi HC’s tiered approach to patent appeals in Esteve Pharmaceuticals, the PABS Annex of the WHO Pandemic Agreement, to key judicial decisions and national and international IP updates. Anything we missed out on? Drop a comment below to let us know! Highlights of the Week

SpicyIP Weekly Review (October 12-October 18) Read More »

The Ghost of Section 100’s Past!

As Halloween approaches, a particular editorial at ET seems spooked by the prospect of lawful and equitable access to medicines! In doing the opposite of what its title suggests, ‘Protect Patients and Patents Smartly’, the editorial piece published on October 15, 2026 is an unfortunate example of legal misinformation and misinterpretation, stuck in the old binary of access versus patent. This published piece runs contrary to years of judicial wisdom, contradicts itself, conflates different legal questions and advocates for a

The Ghost of Section 100’s Past! Read More »

Ribociclib: Access to Medicine Collides with Patent, Price and Policy

In this co-authored post, Ambika and Rishabh break down the recent Kerala High Court ruling on government use of patented inventions under Section 100 and situate it in the broader context of other Ribociclib patents and pending litigations that will impact the drug’s access; all this, at a time when patent enforcement and drug pricing rules might be changing. The judgment’s epilogue references popular cinema for recall value (see pg 56 here), but the real blockbuster of this story is

Ribociclib: Access to Medicine Collides with Patent, Price and Policy Read More »

Scroll to Top